Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy
✍ Scribed by Sylvie Chevillard; Pierre Pouillart; Chérif Beldjord; Bernard Asselain; Philippe Beuzeboc; Henri Magdelénat; Philippe Vielh
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 698 KB
- Volume
- 77
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
The authors examined the relevance of S-phase fraction (SPF) and multidrug resistance (MDR) phenotype as predictive tests of breast cancer response in a series of patients treated by conventional doses of neoadjuvant chemotherapy with (FAC) or without (FTC) doxorubicin.
METHODS.
Fine needle samplings of tumors were used to measure SPF by flow cytornetry before treatment (Day 01, and to assess the MDR phenotype using semiquantified reverse transcriptase polymerase chain reaction and immunocytochemistry, before and after (Days 8 and 28) the first cycle of chemotherapy.